NCT05791474View on ClinicalTrials.gov

ATI-2231 in Advanced Solid Tumor Malignancies

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 15, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Advanced Solid TumorAdvanced Solid Tumor Malignancies
Interventions
DRUG

ATI-2231

Provided by Aclaris Therapeutics, Inc.

Sponsors
All Listed Sponsors
collaborator

Aclaris Therapeutics, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER